Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.

Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat intraocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject’ eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The disclosure teaches methods of utilizing precisely engineered biodegradable drug delivery systems to treat ocular conditions. In aspects, the disclosure provides methods of treating elevated intraocular pressure with intracameral implants administered to the anterior region of an eye. Furthermore, the disclosure provides for methods of lowering intraocular pressure in a subject, by administering intracameral implants that maintain a multi-month sustained level of travoprost acid in the aqueous humor of said subject' eye, which is at least 8× lower than the EC50 values of travoprost acid on its molecular target, but yet still achieves clinically significant lowering of IOP.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.

Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise ocular implants having a desired extended drug release profile suitable for treating elevated intraocular pressure.